About TESARO
TESARO is a Healthcare company based in Waltham (United States) founded in 2010, and was acquired by GSK in December 2018. Oncology therapeutics for cancer treatment and nausea prevention are developed. It operates on a Direct-to-Consumer (D2C) model. TESARO has raised $161 million across 6 funding rounds from investors including Oracle, Kleiner Perkins and T. Rowe Price. TESARO offers products and services including PARP Inhibitors. Its focus areas include Pharmaceuticals and Oncology. Its competitors include Moderna, BeiGene and Incyte; 2 of its 3 listed competitors have raised funding.
Company details
TESARO, based in the United States, is engaged in the development of oncology-focused pharmaceutical products. The company specializes in PARP inhibitors, which are used in the treatment of ovarian cancer, particularly for patients with genetic mutations such as BRCA. These inhibitors are recognized for their potential to transform cancer treatment by preventing cancer cells from repairing damaged DNA. TESAROs solutions are applied in second-line maintenance therapy and show promise for broader application in first-line maintenance settings across multiple cancer types.
Products & Services of TESARO
TESARO offers a comprehensive portfolio of products and services, including PARP Inhibitors.
Medicines for treating ovarian cancer are developed here.
Apps and channels of TESARO
its YouTube channel ViiV Healthcare has 133 subscribers and 30 videos.
Videos from TESARO
The most watched videos on TESARO's YouTube channel, ViiV Healthcare (133 subscribers). Click a video to play it here.
More on ViiV Healthcare.
Funding Insights of TESARO
TESARO has successfully raised a total of $161M across 6 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $161M
- Total Rounds 6
- First Round $60M
(May 2010)
- Investors Count 10
All 6 funding rounds of TESARO with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2018 | Post-IPO | β | β | ||
| Nov 2017 | $500M | Debt – Conventional | β | β | β |
| Apr 2016 | $50M | Post-IPO | β | β | β |
| Feb 2016 | $155M | Post-IPO | β | β | |
| Jun 2011 | $101M | Series B | β | Kleiner Perkins | |
| May 2010 | $60M | Series A | β | New Enterprise Associates | β |
11 investors in total: 11 institutional.
Investors in TESARO
TESARO has secured backing from 11 investors, including venture fund and institutional investors. Prominent investors backing the company include Oracle, Kleiner Perkins and T. Rowe Price.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Global private equity investments are managed by the firm. | athyrium.com | New York, United States | ||
Early-stage investing in IT and healthcare ventures. | interwest.com | |||
Venture capital investments are offered to startups by NEA. | nea.com | Menlo Park, United States | ||
Venture capital firm investing in early-stage tech startups | 1972 | kleinerperkins.com | Menlo Park, United States | |
Private equity and hedge fund investments in healthcare are managed. | ally-bridge.com | Hong Kong, China | ||
VC firm focusing on life science sector | pappas-capital.com | Durham, United States | ||
Healthcare ecosystem is supported through investment and innovation by Deerfield. | deerfield.com | New York, United States | ||
Sovereign Wealth Fund of Government of Australia | futurefund.gov.au | Melbourne, Australia | ||
Diversified asset management services are provided to investors globally. | 1937 | troweprice.com | Baltimore, United States | |
Hybrid cloud infrastructure solutions are delivered for business management. | 1977 | oracle.com | Austin, United States |
Investor details for TESARO
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of TESARO
19 people are tracked at TESARO (8 in leadership, 11 in team).
| Name | Role | Group |
|---|---|---|
Mary Lynne Hedley | President, Chief Operating Officer | Leadership |
Jennifer Jackson | Senior Vice President, Global Regulatory Affairs & Quality Assurance | Leadership |
William Aitchison | Senior Vice President, Technical Operations | Leadership |
Allene Diaz | Senior Vice President, Global Commercial Development and Program Strategy | Leadership |
Erin Wilkie | Director, Global Brand Analytics | Leadership |
Pattie Skeens | Associate Director, Gcp/glp Quality Assurance | Leadership |
Dennis L. Vargo | Vice President And Head Of Pharmacovigilance | Leadership |
Joachim Borchardt-Wagner | Market Access Director DACH | Leadership |
Blanca Gago Cao | Executive Office Assistant | Team |
Michele Musial | Executive Assistant | Team |
Kristina Sukennik Pharmd | Drug Safety/pv Specialist Via Gemini Staffing Consultants | Team |
Zachary Yates | Senior Manager | Team |
Eileen Troy | Manager Quality Control | Team |
Jeffrey Flebbe | Manager, Quality Control | Team |
Nianyun Chen (Chenny) | Senior Manager | Team |
Dominique Demaria | Proxy Auditor | Team |
Joydeep Basu | QA Manager | Team |
Zina D. | Manager, Commercial Quality Control | Team |
Susan Madden | Executive Administrative Assistant | Team |
Complete people profiles for TESARO
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of TESARO
5 dated milestones of TESARO across 8 years, from founding to its latest funding, stage changes and deals.
- Founded TESARO is founded.
- Funding First funding round of $60.0M.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO,.
- Exit Acquired by GSK.
Competitors of TESARO
TESARO has 3 listed competitors in our database, 2 of them funded. They include Moderna, BeiGene and Incyte.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| beigene.com | 2010 | Cambridge, United States | $172M | 1,090 | Targeted and immune-oncology drugs for cancer treatment are developed. | |
| incyte.com | 1991 | Wilmington, United States | 1,387 | Small molecules are developed for cancer and skin disease treatments. |
Detailed competitors of TESARO
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of TESARO
Websites that share an audience with TESARO (tesarobio.com).
Websites whose visitors overlap most with TESARO. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| centerwatch.com | 100% | 158.2K | #254,725 | View details | |
| progenics.com | 94% | View details | |||
| cancer.gov | 92% | 3.1M | #23,691 | View details | |
| fiercebiotech.com | 89% | 858.3K | #81,022 | View details | |
| dana-farber.org | 80% | 549.8K | #114,885 | View details | |
| β’β’β’β’β’β’β’β’β’β’ | β’β’β’β’β’β’.com | β’β’% | β’.β’M | #β’β’β’β’β’ | β |
| β’β’β’β’β’β’β’β’β’β’ | β’β’β’β’β’β’.com | β’β’% | β’.β’M | #β’β’β’β’β’ | β |
| β’β’β’β’β’β’β’β’β’β’ | β’β’β’β’β’β’.com | β’β’% | β’.β’M | #β’β’β’β’β’ | β |
All 11 similar websites and full traffic analytics for TESARO
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 11 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Oncology
3 companies that operate in the same segment as TESARO (Oncology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Tesaro
Complete news archive for TESARO
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about TESARO
TESARO was founded in 2010.
TESARO is headquartered in Waltham, United States. It is registered at Waltham, Massachusetts, United States.
TESARO is a funded company, having raised a total of $161M across 6 funding rounds to date. The company's 1st funding round was a Series A of $60M, raised on May 2010.
TESARO, based in the United States, is engaged in the development of oncology-focused pharmaceutical products. The company specializes in PARP inhibitors, which are used in the treatment of ovarian cancer, particularly for patients with genetic mutations such as BRCA. These inhibitors are recognized for their potential to transform cancer treatment by preventing cancer cells from repairing damaged DNA. TESAROs solutions are applied in second-line maintenance therapy and show promise for broader application in first-line maintenance settings across multiple cancer types.
TESARO offers PARP Inhibitors.
TESARO has 11 investors. Key investors include Oracle, Kleiner Perkins, T. Rowe Price, GSK, and Athyrium Capital Management.
Yes. TESARO was acquired by GSK in December 2018.

